Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

pembrolizumab 224Cyclophosphamide 192Radiotherapy 183Nivolumab 180Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 104Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 91Ipilimumab 81Doxorubicin 79Lenalidomide 76durvalumab 75Rituximab 75atezolizumab 72Radiation 72venetoclax 69fludarabine 68Standard of Care 68Gemcitabine 68Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × seclidemstat × Clear all
NCT04734990 2026-04-02

Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
24 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡